Prostate cancer is the most commonly diagnosed cancer in men in most developed countries, including the UK. The lifetime risk of prostate cancer in men in Europe and North America is about 30%.
While prostate cancer is distressing and potentially fatal if left untreated, it's important to know that many men die with, rather than from, prostate cancer. The risk of dying from prostate cancer is only around 3% - and many cases do not warrant treatment.
Please note: the information below does not constitute medical advice. If you have any concerns at all, speak to your GP or consultant.
CLICK HERE TO DOWNLOAD OUR BITESIZE GUIDE (PDF)
If you are worried about your urinary symptoms, download the My WaterWorks Medical app and fill in the questionnaire which can be presented to your GP.
Donate today to be a part of this fight. Or, to find out other ways you could support TUF, visit our Get Involved page.
Early detection is critical: about 98 % of men with low-grade cancers live for more than 5 years. But, about 70% of men with advanced (metastatic) prostate cancer will die within 5 years.
Age is the single greatest risk factor for prostate cancer. The older you are, the higher your chance of developing the disease. Other risk factors include close relatives with the condition, and a diet high in saturated fats such as those from cheese and red meat. It also occurs more frequently in Afro-Caribbean populations and less in men of Asian origin.
Men with prostate cancer may have no symptoms at all or they might experience a variety of different symptoms, including:
Here's a little clip of TUF supporter, Stephen Fry, talking about his experience of Prostate Cancer.
Donate today to be a part of this fight. Or, to find out other ways you could support TUF, visit our Get Involved page.
Prostate cancer may be diagnosed due to symptoms, or as a result of regular tests and check-ups.
Anyone with suspected prostate cancer should have three specific tests.
A pathologist will study the biopsy results. If cancer is present, it is given a “Gleason Score”. This is a number that describes the cancer's aggressiveness, ranging from 1 to 10, with 1 being the least aggressive.
Donate today to be a part of this fight. Or, to find out other ways you could support TUF, visit our Get Involved page.
Patients with prostate cancer have access to several treatment options, and some promising new therapies. The right treatment depends on the exact type and aggressiveness of the cancer. A urologist will discuss your options before making a decision.
This option is appropriate for:
Careful follow-up with regular DRE and PSA monitoring is essential. However, the patient needs to be offered counselling and active treatment if the cancer progresses.
With locally advanced prostate cancer, the cancerous cells have spread to the seminal vesicles or the bladder, but not to the lymph nodes or bones. The PSA is normally more than 10ng/ml. In this case, surgery is often avoided, and radiotherapy and hormone therapy are preferred.
Treatment of locally advanced disease is unlikely to cure the cancer. The aims are to slow progression of the cancer and to improve quality of life.
Metastatic prostate cancer is where the cancer has spread to other parts of the body.
The PSA level will often be highly elevated and scans will show how the cancer has spread. Lymph nodes may also be enlarged.
This form of prostate cancer has the worst outlook: about 70% of men with metastatic cancer will die within 5 years. Fortunately, there are options that can delay the progression for several years.
All men with prostate cancer have regular PSA checks. After radical prostatectomy the PSA should remain at zero if all of the cancer has been removed. With locally advanced and metastatic disease treated with hormones, the PSA should initially fall to very low levels. However, the cancers eventually become insensitive to hormone therapy and the PSA begins to rise.
This PSA rise often brings clinical symptoms, especially bone pain. Quite often a bone scan will need to be repeated to see whether there has been any spread of the cancer. If the PSA does rise there are other therapeutic options, but none of them will offer a cure. Options include:
If you're worried about prostate cancer symptoms and treatment, speak to your GP.
Donate today to be a part of this fight. Or, to find out other ways you could support TUF, visit our Get Involved page.
Mr Prasanna Sooriakumaran – Researching the impact of surgery on the most deadly forms of prostate cancer
Prostate cancer is at its most deadly when it has spread to the bones. Prasanna (known as PS) is researching how surgery could be used to treat the most deadly forms of prostate cancer.
Often when prostate cancer spreads to the bones a patient won’t be recommended for surgery because they are considered not to be young and healthy enough. PS is running a research project that is looking to challenge that notion with empirical evidence.
PS has recruited 51 men from across the UK who have prostate cancer that has spread to the bones. The next step for PS is to randomise treatment for this group, so that some receive traditional treatments, like hormones, and others receive surgery as well as hormones. PS will analyse the results and see if surgery has made a difference.
“If we can prove that surgery can stop or slow down the most deadly forms of prostate cancer, we could help millions of men with prostate cancer across the world. The results of this study are widely anticipated by urological and oncological societies worldwide, and it’s thanks to TUF that the UK leads this important work.” - PS
Mr Ashwin Sachdeva - Targeting mitochondria to treat prostate cancer
Ashwin is based in Newcastle and is using funding from TUF to research whether defective mitochondria is speeding up the effects of prostate cancer.
Mitochondria are in every cell in our body. They play a crucial role in producing energy for the cell and contain their own DNA. This DNA accumulates errors as a part of the normal ageing process of our bodies, which has a negative effect on how the mitochondria function.
Ashwin’s research has so far shown that defective mitochondria (those that have errors in their DNA) are actually slowing down the progress of prostate cancer. Ashwin’s hope is that, once he has proven this theory, this could allow for the development of drugs to target mitochondria which could slow down prostate cancer.
Donate today to be a part of this fight. Or, to find out other ways you could support TUF, visit our Get Involved page.
All of the work that we do to fight urology disease is funded by supporters across the country. Without support from people like you, we cannot do what we do.
When you donate to The Urology Foundation you join the front line of the fight against urology disease. Your money helps us to:
Donate today to be a part of this fight. Or, to find out other ways you could support TUF, visit our Get Involved page.